article thumbnail

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

Bio Pharma Dive

The findings, from two trials involving tens of thousands of women, could influence guidelines around the use of hormonal treatment for menopausal symptoms.

Hormones 290
article thumbnail

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

Pharmaceutical Technology

Ascendis Pharma has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for TransCon hGH to treat adults with growth hormone deficiency (GHD).

Hormones 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mira’s New Menopause Transitions Kit Allows for At-Home Hormone Monitoring

XTalks

Mira, a California-based women’s health technology company, has introduced its Menopause Transitions Kit, a new hormone monitoring kit designed for menopausal women. The at-home device enables women to track key hormone levels, offering real-time insights into the complex hormonal fluctuations associated with perimenopause and menopause.

article thumbnail

Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions

Pharmaceutical Technology

Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and SSTR2 activity regulation.

Hormones 130
article thumbnail

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

Fierce Pharma

After two delays, the FDA has finally signed off on Ascendis Pharma's hormone replacement therapy Yorvipath, also known as TransCon PTH, which is the first approved product for hypoparathyroidism in adults in the U.S. Ascendis Pharma should be well prepared for the U.S.

Hormones 125
article thumbnail

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months

Fierce Pharma

It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide).

Hormones 118
article thumbnail

The end of condoms? Will men embrace the hormone-free birth control pill?

Outsourcing Pharma

In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.